China Pneumococcal Vaccine Market Size & Outlook, 2023-2030
China pneumococcal vaccine market, 2018-2030 (US$M)
Related Markets
China pneumococcal vaccine market highlights
- The China pneumococcal vaccine market generated a revenue of USD 142.8 million in 2023 and is expected to reach USD 430.8 million by 2030.
- The China market is expected to grow at a CAGR of 17.1% from 2024 to 2030.
- In terms of segment, pneumococcal conjugate vaccine was the largest revenue generating vaccine type in 2023.
- Pneumococcal Conjugate Vaccine is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Pneumococcal vaccine market data book summary
| Market revenue in 2023 | USD 142.8 million |
| Market revenue in 2030 | USD 430.8 million |
| Growth rate | 17.1% (CAGR from 2023 to 2030) |
| Largest segment | Pneumococcal conjugate vaccine |
| Fastest growing segment | Pneumococcal Conjugate Vaccine |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
Other key industry trends
- In terms of revenue, China accounted for 1.8% of the global pneumococcal vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China pneumococcal vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 347.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pneumococcal Vaccine Market Scope
Pneumococcal Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China pneumococcal vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93% in 2023. Horizon Databook has segmented the China pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In January 2020, China introduced its first domestically produced 13-valent pneumococcal conjugate vaccine, marking a significant milestone in the country's healthcare sector. This vaccine, developed independently in China, aimed to address the significant burden of pneumococcal disease, particularly among children under the age of 5, and challenge the market dominance of international players like Pfizer.
However, Pfizer's Prevenar 13, a well-established product in the pneumococcal vaccine market, faced a strategic shift in November 2023. Pfizer decided to dissolve its 400-member team responsible for Prevenar 13 in China and transfer the distribution and promotion rights to Beijing Keyocean Pharmaceutical Co., Ltd., reflecting changes in the competitive landscape.
Furthermore, Pfizer's decision to reduce its workforce in China aligns with a broader trend of global restructuring efforts within the company, aiming to optimize operations and adapt to changing market conditions. By forging strategic partnerships and focusing on efficiency, Pfizer aims to sustain its presence and competitiveness in the dynamic China pneumococcal vaccine market.
Reasons to subscribe to China pneumococcal vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China pneumococcal vaccine market databook
-
Our clientele includes a mix of pneumococcal vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China pneumococcal vaccine market, including forecasts for subscribers. This country databook contains high-level insights into China pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China pneumococcal vaccine market size, by vaccine type, 2018-2030 (US$M)
China Pneumococcal Vaccine Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
